From Trial to Practice: Interpreting 52-Week MINT Findings in Generalized Myasthenia Gravis

Richard Nowak, MD, MS, outlines the biologic rationale for CD19-targeted therapy in generalized myasthenia gravis, highlighting how inebilizumab differs from CD20-directed approaches and why broader B-cell depletion may offer clinical advantages.

Richard Nowak, MD, MS, outlines the design of the phase 3 MINT trial, highlighting its patient population, forced steroid taper, and the rationale for extending evaluation to a 52-week randomized control period.

Richard Nowak, MD, MS, reviews 52-week efficacy data from the MINT trial, highlighting durable improvements in MG-ADL and QMG scores and what the evolving treatment-placebo separation means for long-term disease control.

Richard Nowak, MD, MS, discusses pharmacodynamic findings from the MINT trial, highlighting rapid and sustained B-cell depletion with inebilizumab and the current limitations of biomarkers in predicting clinical response.

Richard Nowak, MD, MS, discusses how inebilizumab fits within the current gMG treatment landscape, highlighting its upstream CD19-targeted mechanism and sustained clinical benefit compared with other biologic strategies.

Richard Nowak, MD, MS, discusses remaining questions surrounding inebilizumab in generalized myasthenia gravis, including long-term durability, biomarker development, and the need for real-world and expanded population data.